This opportunity is no longer accepting applications.
grant RFA-HL-23-012

Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)

This grant offers early-stage funding to help researchers identify lead compounds for developing treatments for heart, lung, blood, and sleep diseases. It is part of a Catalyze initiative designed to advance projects so they can qualify for further development programs or attract additional support from federal or private partners for preclinical work.

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innov…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Heart, Lung, and Blood Institute

Awards & funding

Award Ceiling: $350,000
Award Amount: $350,000

Dates

Opportunity Released: January 24, 2022
Open for Submission: January 24, 2022
Submission Deadline: December 20, 2024
Application Window Closes: December 20, 2024

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.